Dimitrios Salgkamis

Publications
CV
Public outreach and news

Articles

Journal article: ANNALS OF ONCOLOGY. 2025;36:s1033-s1034
1771eP Liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis
Filis P; Pagkalidou E; Tsiknakis N; Salgkamis D; Zerdes I; Markozannes G; Manou M; Papakonstantinou A; Tsilidis K; Matikas A; Foukakis T
Journal article: CLINICAL CANCER RESEARCH. 2025;31(12_Supplement):p4-01-30-p4-01-30
Abstract P4-01-30: Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment
Wang K; Gaessler LF; Zerdes I; Zhu Y; Sifakis E; Salgkamis D; Harbers L; Crosetto N; Bergh J; Hatschek T; Johansson HJ; Matikas A; Lehtiö J; Foukakis T
Journal article: CLINICAL CANCER RESEARCH. 2025;31(12):p2-01-30-p2-01-30-P20130
Gene Expression patterns in early ER+/HER2-breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial
Tzoras E; Sarafidis M; Sifakis EG; Salgkamis D; Acs B; Sun W; Zerdes I; Wang K; Bergh J; Hatschek T; Matikas A; Foukakis T
Journal article: ESMO OPEN. 2025;10:104574
20P Evolution of early-stage ERBB2-mutant, HER2+ breast cancer under neoadjuvant therapy
Wang K; Zerdes I; Sifakis EG; Salgkamis D; Bergh J; Hatschek T; Matikas A; Foukakis T
Journal article: ESMO OPEN. 2025;10:104584
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy
Zerdes I; Wang K; Manikis G; Salgkamis D; Zhu Y; Tzoras E; Mezheyeuski A; Acs B; Sifakis EG; Hartman J; Papakonstantinou A; Matikas A; Bergh J; Hatschek T; Foukakis T
Journal article: ESMO OPEN. 2025;10:104559
4MO Development and validation of CDKPredX, a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2- breast cancer: Correlative analysis of the randomized phase II PREDIX luminal B trial
Foukakis T; Tzoras E; Sarafidis M; Sifakis EG; Salgkamis D; Zerdes I; Wang K; Pascual T; Gavilá-Gregori J; Villacampa G; Prat A; Perou CM; Bergh J; Hatschek T; Matikas A
Journal article: ESMO OPEN. 2025;10:104632
78P Validation of an AI-based solution for breast cancer risk stratification using digital H&E images: Subgroup analysis within PANTHER clinical trial
Tzoras E; Salgkamis D; Tsiknakis N; Johansson H; Sun W; Hellström M; Andersson A; Loibl S; Untch M; Denkert C; Jank P; Rantalainen M; Hartman J; Zerdes I; Matikas A; Bergh J; Foukakis T
Journal article: ESMO OPEN. 2025;10:104589
35P Deep learning for overall survival risk prediction in early breast cancer using H&E-stained images and clinicopathological variables
Tsiknakis N; Salgkamis D; Tzoras E; Manikis G; Liu X; Marias K; Acs B; Hartman J; Hellström M; Johansson H; Andersson A; Loibl S; Untch M; Denkert C; Jank P; Zerdes I; Matikas A; Bergh J; Foukakis T
Journal article: ESMO OPEN. 2025;10:104631
77P The landscape of somatic mutations in high-risk early ER+/HER2- breast cancer patients: Analysis of the randomized phase II PREDIX luminal B trial
Sarafidis M; Tzoras E; Sifakis EG; Wang K; Salgkamis D; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
Journal article: ESMO OPEN. 2025;10:104609
55P Single-nucleotide polymorphisms associated with haematological toxicities during adjuvant chemotherapy in high-risk early breast cancer patients: Results from the PANTHER phase III trial
Salgkamis D; Liu X; Rivera N; Papakonstantinou A; Hellström M; Agartz S; Sifakis EG; Zerdes I; Bergh J; Matikas A; Foukakis T
Article: IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS. 2024;28(9):5312-5322
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images
Tsiknakis N; Manikis G; Tzoras E; Salgkamis D; Vidal JM; Wang K; Zaridis D; Sifakis E; Zerdes I; Bergh J; Hartman J; Acs B; Marias K; Foukakis T
Article: SCIENTIFIC REPORTS. 2024;14(1):18275
Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue
Salgkamis D; Sifakis EG; Agartz S; Wirta V; Hartman J; Bergh J; Foukakis T; Matikas A; Zerdes I
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2024;2024:1-5
Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast Histopathology.
Tsiknakis N; Wang K; Salgkamis D; Tzoras E; Manikis GC; Sifakis E; Bergh J; Zerdes I; Marias K; Matikas A; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T

All other publications

Conference publication: CLINICAL CANCER RESEARCH. 2025;31(12)
Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment
Wang K; Gaessler LF; Zerdes I; Zhu Y; Sifakis E; Salgkamis D; Harbers L; Crosetto N; Bergh J; Hatschek T; Johansson HJ; Matikas A; Lehtioe J; Foukakis T
Review: DRUG DISCOVERY TODAY. 2025;30(1):104250
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
Filis P; Salgkamis D; Matikas A; Zerdes I
Meeting abstract: CANCER RESEARCH. 2024;84(9):po2-07-06-po2-07-06
Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Sifakis E; Manikis G; Salgkamis D; Tsiknakis N; Harbers L; Crosetto N; Bergh J; Matikas A; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103075
69P Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides
Tsiknakis N; Salgkamis D; Tzoras E; Wang K; Liu X; Manikis G; Sifakis EG; Bergh J; Marias K; Zerdes I; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103063
56P Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial
Zerdes I; Wang K; Salgkamis D; Zhu Y; Sifakis EG; Acs B; Hartman J; Hatschek T; Bergh J; Matikas A; Foukakis T
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2024;200:113830
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer
Foukakis T; Wang K; Zerdes I; Zhu Y; Sifakis E; Tsiknakis N; Manikis G; Salgkamis D; Harbers L; Bergh J; Johansson H; Crosetto N; Lehtio J; Matikas A; Hatschek T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p5-02-20-p5-02-20
Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Matikas A; Sifakis E; Salgkamis D; Bjohle J; Elinder E; Margolin S; Campos AB; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Johansson H; Hellstrom M; Azavedo E; Hartman J; Bergh J; Hatschek T; Foukakis T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02
Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial
Zerdes I; Salgkamis D; Matikas A; Selander L; Wang K; Tzoras E; Sifakis E; Agartz S; Chen X; Hellstrom M; Hartman J; Bergh J; Foukakis T; Hatschek T
Conference publication: CANCER RESEARCH. 2021;81(4_Supplement):ps18-27-ps18-27
Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Conference publication: CANCER RESEARCH. 2021;81(4)
Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T

Employments

Clinical Assistant, Department of Oncology-Pathology, Karolinska Institutet, 2026-2026
Phd Student, Department of Oncology-Pathology, Karolinska Institutet, 2022-2026

Articles

All other publications

Employments

News from KI

Events from KI